A
28.57
0.43 (1.53%)
| Previous Close | 28.14 |
| Open | 28.32 |
| Volume | 1,125,090 |
| Avg. Volume (3M) | 2,534,700 |
| Market Cap | 3,608,102,656 |
| Price / Earnings (Forward) | 46.30 |
| Price / Sales | 3.83 |
| Price / Book | 18.67 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -28.83% |
| Operating Margin (TTM) | -49.96% |
| Diluted EPS (TTM) | -1.80 |
| Quarterly Revenue Growth (YOY) | -3.20% |
| Total Debt/Equity (MRQ) | 285.94% |
| Current Ratio (MRQ) | 4.08 |
| Operating Cash Flow (TTM) | -8.29 M |
| Levered Free Cash Flow (TTM) | 45.63 M |
| Return on Assets (TTM) | -14.20% |
| Return on Equity (TTM) | -103.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Apellis Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
-1.0
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.5 |
| Average | -1.00 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 13.69% |
| % Held by Institutions | 104.60% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (Baird, 82.01%) | Buy |
| Median | 40.50 (41.76%) | |
| Low | 18.00 (Goldman Sachs, -37.00%) | Sell |
| Average | 36.50 (27.76%) | |
| Total | 6 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 21.76 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 05 Nov 2025 | 36.00 (26.01%) | Buy | 19.95 |
| Mizuho | 03 Nov 2025 | 19.00 (-33.50%) | Hold | 20.69 |
| Baird | 31 Oct 2025 | 52.00 (82.01%) | Buy | 21.47 |
| Citigroup | 31 Oct 2025 | 45.00 (57.51%) | Buy | 21.47 |
| HC Wainwright & Co. | 31 Oct 2025 | 45.00 (57.51%) | Buy | 21.47 |
| TD Cowen | 31 Oct 2025 | 45.00 (57.51%) | Buy | 21.47 |
| Wells Fargo | 15 Oct 2025 | 32.00 (12.01%) | Buy | 25.22 |
| Goldman Sachs | 26 Sep 2025 | 18.00 (-37.00%) | Sell | 22.37 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Nov 2025 | Announcement | Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference |
| 30 Oct 2025 | Announcement | Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results |
| 20 Oct 2025 | Announcement | New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week |
| 16 Oct 2025 | Announcement | Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results |
| 27 Aug 2025 | Announcement | Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |